LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Clinical trials for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL explained in plain language.
Never miss a new study
Get alerted when new LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL trials appear
Sign up with your email to follow new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New antibody therapy targets Hard-to-Treat blood cancers
Disease control OngoingThis early-stage study tests a new drug, JNJ-80948543, designed to help the body's immune cells attack cancer. It is for adults with certain blood cancers (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have not responded to other treatments. The main goals are to che…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 09:29 UTC
-
New CLL strategy spares patients unnecessary drugs
Disease control OngoingThis study tests a new way to treat chronic lymphocytic leukemia (CLL) using two oral drugs, zanubrutinib and venetoclax. Instead of giving everyone a third drug from the start, only patients who still have signs of cancer after initial treatment will receive the additional drug …
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 26, 2026 09:27 UTC
-
Blood cancer drug safety tracked over 5 years
Disease control OngoingThis study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. Participants must have already completed an earlier study and still benefit from the drug. They receive treatment ev…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New pill combo shows promise in battling blood cancer
Disease control OngoingThis phase 3 study tests whether a combination of two targeted drugs, ibrutinib and venetoclax, works better than the current standard therapy for adults with chronic lymphocytic leukemia (CLL) who are older or have other health issues. About 211 participants will receive either …
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New pill shows promise in battling advanced blood cancers
Disease control OngoingThis early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like certain leukemias, lymphomas, and multiple myeloma) who have already tried standard treatments. The main goals are to find the safest dose and to see if the drug can shri…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 12, 2026 13:51 UTC
-
Cancer patients monitored for long-term side effects in safety study
Knowledge-focused ENROLLING_BY_INVITATIONThis study enrolls 120 people with different cancers who already received treatment in an earlier study. The goal is to track serious side effects and other health issues over time. No new treatment is given; participants are simply monitored for safety.
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Knowledge-focused
Last updated May 26, 2026 09:27 UTC